Anna palautettaMene vanhalle sivulle
Copyright © Inderes 2011 - present. All rights reserved.

Saniona is presenting at Redeye Growth Day June 1, 2023

Lehdistötiedote
Saniona

Saniona (OMX: SANION), clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels, today announced that it will present at Redeye Growth Day June 1, 2023. Details are as follows:

On June 1st at 9.40 CEO Thomas Feldthus will discuss the latest developments in Saniona at Redeye Growth Day 2023. The In Focus interview is live broadcasted and can be followed at

https://www.redeye.se/events/871323/redeye-growth-day

To get an preparatory introduction to Saniona please watch the Company Presentation here

https://www.redeye.se/video/company-prerecorded-presentation/911077/saniona-2

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; [email protected]

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. Saniona’s most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity by Saniona’s partner Medix. Saniona is advancing four product candidates including Tesomet™ and three ion channel modulators SAN711, SAN903 and SAN2219. Tesomet™ has progressed to mid-stage clinical trials for rare eating disorders. SAN711 has completed Phase 1 for neuropathic pain conditions. SAN903 is ready for Phase 1 for inflammatory and fibrotic disorders. SAN2219 is in preclinical development for epilepsy. Saniona has research and development partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cephagenix ApS. Saniona is based in Copenhagen, and listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachments
Saniona is presenting at Redeye Growth Day June 1, 2023